1. Introduction {#s0005}
===============

Circadian rhythms and energy metabolism are inextricably linked. While many behavioral and physiological processes linked to energy metabolism show daily fluctuations under the control of an endogenous circadian clock and environmental cues, the circadian clock is itself influenced by feeding and activity rhythms, and ultimately metabolic state [@bib1; @bib2; @bib3]. The regulation of body metabolism by normal circadian rhythms has important clinical implications, since chronic circadian misalignment, as occurs in shift work, is associated with a higher prevalence of insulin resistance, obesity, metabolic syndrome and diabetes [@bib4; @bib5; @bib6].

The circadian timing system is composed of a central pacemaker located in the suprachiasmatic nucleus (SCN) of the hypothalamus and autonomous molecular oscillators present in all cells of the body. At the cellular level, the core of this 24-h rhythm generating oscillator is composed of molecular feedback loops [@bib7]. In the major loop, the transcription factors BMAL1 and CLOCK bind as heterodimers to the promoters of *Per* and *Cry* genes inducing their transcription. Through negative feedback, PER and CRY proteins translocate to the nucleus and repress the CLOCK:BMAL1 complex. In a second regulatory loop, the expression of *Bmal1* (*Arntl*) is controlled by CLOCK:BMAL1-dependent transcriptional activators of the ROR family, such as RORα, and repressors of the REV-ERB family, such as REV-ERBα. In addition to the core clock genes, all tissues contain a large number of oscillating genes, most of which are tissue-specific and regulated either directly by the core oscillator or by extrinsic circadian signals [@bib7].

An important role for circadian clocks in the regulation of glucose metabolism is supported by genome-wide DNA-binding analyses and by ablation of clock genes. A time-resolved and genome-wide map of BMAL1 binding in mouse liver, derived from ChIP-seq analyses, has shown that carbohydrate metabolism is a major output of the circadian clock in this tissue [@bib8]. Global inactivation of different clock genes leads to altered glucose metabolism: *Clock* mutant mice display hyperglycemia, obesity and metabolic syndrome [@bib9]; *Per1*/*Per2* double knockout mice and *Cry1*/*Cr2* double knockout mice exhibit glucose intolerance [@bib10; @bib11]; *Bmal1* null mice are also glucose intolerant, and show altered gluconeogenesis [@bib10; @bib12]. In addition, the normal circadian rhythm of increased insulin sensitivity during the active/feeding phase is completely abolished in global *Bmal1* null mice [@bib13].

Interpretation of whole body knockout studies is complicated by the fact that all tissues are affected, including both the central pacemaker and peripheral clocks. The hierarchical role of the central pacemaker was demonstrated by the finding that circadian rhythms of blood glucose, insulin and glucagon, as well as glucose tolerance, are all abolished by SCN lesion [@bib14]. An equally important role for peripheral oscillators has been demonstrated by tissue-specific knockout of clock genes, with distinct effects depending on the tissue. Selective knockout of *Bmal1* in the liver causes hypoglycemia [@bib10], while ablation of the same gene in the endocrine pancreas leads to fasting hyperglycemia and severe glucose intolerance [@bib15]. Local insulin sensitivity was found to be normal in mice lacking *Bmal1* selectively in the liver or adipose tissue [@bib10; @bib16].

Although skeletal muscle is a primary site of insulin-dependent glucose disposal, the specific role the muscle clock plays in regulating glucose uptake and metabolism is not known. A daily rhythm in plasma glucose concentration has been described in both animals and humans, with a peak just before the start of the main activity period, reflecting fluctuations in glucose export, glucose uptake and insulin sensitivity [@bib14]. However, it is not clear whether these circadian rhythms are controlled by peripheral clocks in muscle and adipose tissue, or by humoral or neural signals emanating from the SCN. A circadian rhythm of glucose uptake was also demonstrated in muscle cell cultures, but these daily fluctuations were observed both in basal and insulin-stimulated conditions [@bib17]. To understand the physiological role the intrinsic muscle clock plays in glucose metabolism, we have generated two skeletal muscle-specific *Bmal1* knockout models. We report here that muscle-specific *Bmal1* ablation causes impaired insulin-dependent glucose uptake and reduced glucose oxidation in skeletal muscle, and we identify potential mechanisms involved in mediating these effects.

2. Materials and methods {#s0010}
========================

2.1. Animals {#s0015}
------------

Muscle-specific inactivation of *Bmal1* (mKO) was obtained from the cross between a C57BL/6 mouse line with floxed *Bmal1* [@bib18] and a C57BL/6 mouse line carrying a Cre recombinase transgene under control of the *Mlc1f* promoter (*Mlc1f--Cre*) [@bib19]. In the resulting mKO mice, the region coding for the BMAL1 basic helix--loop--helix DNA binding domain is excised. Cre-negative littermates were used as controls.

A second knockout model with inducible muscle-specific inactivation of *Bmal1* (imKO) was obtained by crossing the *Bmal1* floxed line with mice carrying an α-skeletal actin driven Cre recombinase fused to a mutated estrogen receptor [@bib20], which can be activated by treatment with tamoxifen (i.p. 1 mg/day for 5 days). Cre negative littermates, also receiving tamoxifen treatment, were used as controls. All strains had been backcrossed a minimum of 6 times with C57BL/6 mice. Experimental protocols were reviewed and approved by the local Animal Care Committee, University of Padova. Animals were housed in a temperature-controlled room (22 °C) under a 12 h light--dark regimen, with lights on at ZT0 (6 am), lights off at ZT12 (6 pm), with standard chow diet (Mucedola, Settimo Milanese, Italy) and water provided *ad libitum*. All tissues were collected immediately after cervical dislocation at ZT0, 4, 8, 12, 16, and 20, snap frozen in liquid nitrogen and stored at −80 °C until subsequent use. To monitor locomotor activity levels, a telemetric sensor (PhysioTel, TA10TA-F20, Data Sciences, Inc.) was implanted i.p. under general anesthesia. Mice were allowed to recover for at least 2 weeks, and locomotor activity was recorded continuously for 12 days.

2.2. Immunofluorescence {#s0020}
-----------------------

Cryosections of fast and slow muscles were stained with monoclonal anti-myosin heavy chain (MyHC) antibodies produced in our lab [@bib21], and now distributed by the Developmental Studies Hybridoma Bank (DSHB, University of Iowa): BA-D5 (IgG2b, supernatant, 1:100 dilution) specific for MyHC-I, SC-71 (IgG1, supernatant, 1:100 dilution) specific for MyHC-2A and BF-F3 (IgM, purified antibody, 1:100 dilution) specific for MyHC-2B. Type 2X fibers are not recognized by these antibodies, and so appear black. Three different secondary antibodies (Jackson ImmunoResearch) were used to selectively bind to each primary antibody: goat anti-mouse IgG1, conjugated with DyLight488 fluorophore (to bind to SC-71); goat anti-mouse IgG2b, conjugated with DyLight405 fluorophore (to bind to BA-D5); goat anti-mouse IgM, conjugated with DyLight549 fluorophore (to bind to BF-F3). Muscle sections, 8 µm thick, were incubated with M.O.M. IgG blocking solution (Vector) for 1 h at room temperature, then briefly washed twice with PBS for 2 min. A solution with all the primary antibodies in phosphate-buffered saline (PBS) containing 0.5% of bovine serum albumin (BSA) was then prepared, and sections were incubated for 1 h at 37 °C. After 3 washes (5 min each) with PBS, sections were incubated for 30 min at 37 °C with a solution with the three different secondary antibodies, diluted in PBS containing 0.5% of BSA and 5% of goat serum. After 3 washes with PBS (5 min each) and a brief rinse in water, sections were mounted with Elvanol. A control incubation with no primary antibodies was performed, and also control incubations with each primary antibody and non-specific secondary antibodies to exclude any possible cross-reaction. Pictures were collected with an epifluorescence Leica DM5000 B equipped with a Leica DFC 300 FX camera. Single-color images were merged to obtain a whole muscle reconstruction with Adobe Photoshop CS2 (Adobe Systems Inc.).

2.3. Electron microscopy {#s0025}
------------------------

Muscles were fixed at resting length in 2.5% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4. During subsequent washing in phosphate buffer, small bundles of fibers were dissected from the superficial regions of the muscles and postfixed in 1% OsO~4~ in phosphate buffer and treated with uranyl acetate before dehydration and embedding in Epon. Ultrathin sections were stained with lead citrate.

2.4. Force measurements {#s0030}
-----------------------

*In vivo* force measurements were performed as described previously [@bib22]. Briefly, mice were anesthetized and stainless steel electrode wires were placed on either side of the sciatic nerve. Torque production of the plantar flexors was measured using a muscle lever system (Model 305c; Aurora Scientific, Aurora ON, Canada). The force--frequency curves were determined by increasing the stimulation frequency in a stepwise manner, pausing for 30 s between stimuli to avoid effects due to fatigue. Muscle force was normalized for the weight of the gastrocnemius muscle.

2.5. RNA isolation and qPCR {#s0035}
---------------------------

Total RNA was isolated using TRIzol (Invitrogen) followed by cleanup with the RNeasy Mini Kit (Qiagen). RNA integrity was evaluated with the Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) and quantified with a NanoVue spectrophotometer (GE Healthcare Life Sciences, Baie d\'Urfe, QC). Complementary DNA from each sample was generated from 0.8 μg of RNA reverse-transcribed with Invitrogen Superscript III reverse transcriptase. Primer sets were designed using Primer-BLAST (NCBI) and were each validated prior to use by gradient PCR and gel analysis to test for optimal annealing temperature, reaction efficiency and specificity. Duplicates of cDNA samples were then amplified on the 7900HT Fast Real-Time PCR System (Applied Biosystems) using the Fast SYBR Green RT-PCR kit (Applied Biosystems). Specificity of gene amplification was confirmed by analyzing the dissociation curve with SDS 2.4 software (Applied Biosystems). Analysis was performed using the standard curve method and all data were normalized relative to *36B4* expression and plotted in arbitrary units as mean±SEM. Primer sequences are available upon request.

2.6. Gene expression profiling and analyses {#s0040}
-------------------------------------------

For gene expression profiling, 250 ng of RNA from tibialis anterior and soleus muscles was hybridized to Mouse Gene 1.0 ST Arrays (Affymetrix) using three biological replicates for each time point. Expression values were generated from fluorescence signals using the robust multi-array average procedure (RMA) [@bib23]. Specifically, intensity levels have been background adjusted, normalized using quantile normalization, and log 2 expression values calculated using median polish summarization and Entrez custom chip definition files for mouse arrays (version 14.1.0) [@bib24]. Differentially expressed genes were identified using the microarray Significant Profiles method coded in the maSigPro R package [@bib25] with default parameters. Rhythmic genes that cycle with a 24-h period were identified using a Benjamini--Hochberg *q-*value\<0.2 in the non-parametric algorithm JTK_Cycle [@bib26]. Over-representation analysis was performed using Gene Set Enrichment Analysis software (GSEA; <http://www.broadinstitute.org/gsea/index.jsp>) [@bib27] and gene sets from the KEGG database. Gene sets were defined as significantly enriched if the False Discovery Rate (FDR) was \<0.25 when using Signal2Noise as metric and 10,000 permutations of phenotype labels. Expression data are available at Gene Expression Omnibus under the accession number [GSE43071](ncbi-p:GSE43071){#ir0010}.

2.7. Global metabolic profiling {#s0045}
-------------------------------

Metabolic profiling, peak identification, and curation were performed by Metabolon using described methods [@bib28]. Briefly, the non-targeted metabolic profiling platform used by Metabolon combines three independent platforms: UHPLC/MS/MS optimized for basic species, UHPLC/MS/MS optimized for acidic species, and GC/MS. We examined 60 muscles (tibialis anterior) from distinct mice, corresponding to control and muscle-specific *Bmal1* knockout, at 6 time points, 5 muscles per point. A total of 277 biochemicals were identified, but only sugar metabolites will be reported here (see [Table S1](#s0125){ref-type="sec"}).

2.8. CircadiOmics {#s0050}
-----------------

All transcriptome and metabolome data are accessible through the CircadiOmics Website (<http://circadiomics.igb.uci.edu>), allowing users to search and view genes of interest and detected metabolites in Ctrl and Bmal1 mKO skeletal muscles, as well as their interactions and statistics. Importantly, gene expression and metabolite levels were derived from contralateral hindlimb muscles from the same animals, allowing for a more direct correlation of these metabolite--gene interactions. Networks and subnetworks can be explored and rearranged interactively, providing a comprehensive systems-level view of the circadian molecular pathways [@bib29].

2.9. Comparative analysis of genomic sequences {#s0055}
----------------------------------------------

For the identification of potential binding sites for clock genes, the genomic sequences for 6 eutherian species (about 400 bp upstream and 400 bp downstream of the relevant binding motif) were analyzed using the mVISTA tool (<http://genome.lbl.gov/vista>) and aligned with LAGAN. The conservation parameters were set as 70% of conservation identity and 100 bp minimum conservation window.

2.10. Glucose and insulin tolerance tests {#s0060}
-----------------------------------------

Blood glucose was measured after an 8 h fast using a Glucocard G^+^ meter (Arkray Factory, Shiga, Japan). Glucose tolerance tests (GTT) and insulin tolerance tests (ITT) were performed at ZT12, coinciding with the hours near awakening and the normal physiological peak of glucose tolerance and insulin sensitivity [@bib14]. Mice were fasted for 8 h before analysis during their normal rest/fasting phase. For GTT, mice were injected i.p. with glucose (2 g/kg body weight). Blood glucose was measured at 0, 10, 20, 30, 60 and 120 min via the tail vein. For ITT, mice were injected i.p. with human insulin (0.75 U/kg body weight; Sigma) and blood glucose was measured at −10, 0, 10, 20, 30, 60, and 90 min via the tail vein.

2.11. Insulin-stimulated glucose transport in isolated skeletal muscle {#s0065}
----------------------------------------------------------------------

All experiments were performed between ZT8 and ZT12 in order to coincide with the hours immediately before and during awakening, the normal physiological peak of glucose tolerance and insulin sensitivity [@bib14]. Mice were sacrificed by cervical dislocation and soleus muscles were rapidly and carefully removed. The method to measure glucose transport was similar to that described previously [@bib30; @bib31] with some modifications [@bib32]. Muscles were pre-incubated for 40 min at 30 °C under gentle shaking (200 RPM) in 2 mL of a daily prepared, pre-gassed (1 h, 95% O~2~+5% CO~2~) modified Krebs--Henseleit buffer (KHB): 118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl~2~, 1.2 mM KH~2~PO~4~, 1.2 mM MgSO~4~, 15 mM CO~2~--gassed NaHCO~3~, 1% fatty acid free bovine serum albumin (BSA), 5 mM glucose, and 10 mM HEPES. Thereafter, muscles were incubated an additional 20 min at 30 °C under gentle shaking (200 RPM) in 2 mL KHB+radiolabelled \[^3^H\]-2-Deoxyglucose (2-DG) (1.5 μCi/mL) with either 0, or for contralateral muscles, 2 mU/mL insulin (Sigma). Muscles were quickly removed, rinsed in sterile saline, and washed 3×5 min (100 RPM) in ice-cold KHB to clear extracellular space of 2-DG [@bib33]. Muscles were then rinsed again in sterile saline, blotted with filter paper, weighed, and homogenized in 1 M KOH at 70 °C with periodic agitation for 15 min. Homogenates were centrifuged 10,000*g* at 4 °C for 5 min to clear insoluble components, and supernatants were pipetted into vials with 10 mL scintillation cocktail and \[^3^H\]-2-DG disintegrations per minute (dpm) for each vial were determined using a scintillation counter.

2.12. Glucose oxidation {#s0070}
-----------------------

All experiments were performed on mKO and control mice, and 24-h fasted control mice, between ZT8 and ZT12, again to coincide with the hours near awakening and the normal physiological peak of glucose tolerance and insulin sensitivity [@bib14]. The method to measure glucose oxidation was similar to that previously described [@bib34] with some modifications. Mice were sacrificed by cervical dislocation, and diaphragm muscles were rapidly and carefully removed, blotted, cut in half, weighed, and pre-incubated for 30 min at 37 °C under gentle shaking (200 RPM) in 0.5 mL of a daily prepared, pre-gassed (1 h, 95% O~2~+5% CO~2~) modified Krebs--Henseleit buffer (KHB): 118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl~2~, 1.2 mM KH~2~PO~4~, 1.2 mM MgSO~4~, 15 mM CO~2~^−^gassed NaHCO~3~, 1% fatty acid free BSA, 5 mM glucose, and 10 mM HEPES. Thereafter, muscles were incubated an additional 90 min at 37 °C under gentle shaking (200 RPM) in 0.5 mL KHB+radiolabelled \[1-^14^C\]-glucose (0.5 μCi/mL). Reactions were terminated by addition of 100 μL 1 M perchloric acid, and the CO~2~ produced during the incubation was trapped in 100 μL NaOH that had been added to a small tube inside the reaction vial. Glucose oxidation rates were determined by measuring incorporation into ^14^CO~2~ by liquid scintillation counting.

2.13. PDHa activity {#s0075}
-------------------

The activity of PDH in the active form (PDHa) was determined as previously described [@bib35; @bib36; @bib37] after homogenization of 10--15 mg gastrocnemius muscle on ice, for 50 s using a glass homogenizer (Kontes, Vineland, NJ, USA) and quick-frozen in liquid nitrogen.

2.14. SDS-PAGE and western blotting {#s0080}
-----------------------------------

Muscle lysates were prepared as previously reported [@bib38], protein concentration determined using the bicinchoninic acid assay (Pierce, Rockford, IL, USA) and SDS-PAGE performed using 10% hand-cast gels. Western blotting analysis was performed using specific antibodies to BMAL1 (kind gift from Dr. Charles Weitz), AKT1, AKT2 and HK2 (cell signaling), β Tubulin and Actin (Santa Cruz), phospho-AKT Ser^473^ and phospho-AKT Thr^308^ (Millipore), GLUT4 (Thermo Scientific), TBC1D1 (kind gift from Prof. Dr. Hadi Al-Hasani), PDH-E1α, phospho-PDH-E1α Ser^300^, and PDK4 (kind gifts from Prof. Grahame Hardie) and PDP1 (kind gift from Dr. Brian Robinson). The bands were visualized and quantified (Carestream Health, Rochester, NY, USA), then normalized by an internal standard [@bib38].

2.15. Statistical analysis {#s0085}
--------------------------

All data are expressed as means±SEM unless otherwise stated. Statistical analysis was performed using unpaired Student\'s *t*-test or 2-way analysis of variant (ANOVA). When ANOVA revealed significant differences, further analysis was performed using Bonferroni\'s multiple comparison test. Differences between groups were considered statistically significant for *p*\<0.05.

3. Results {#s0090}
==========

3.1. Muscle-specific *Bmal1* knockout mice {#s0095}
------------------------------------------

To determine the role of the muscle clock, we produced two mouse lines with skeletal muscle-specific knockout of *Bmal1* (*Arntl*), an essential component of the core clock. The first line was a traditional tissue-specific knockout, for which we bred mice with a floxed *Bmal1* allele (*Bmal1fl/fl*) [@bib18] with mice carrying a Cre recombinase transgene under control of the *Mlc1f* promoter (*Mlc1f--Cre*), which is specifically active in skeletal muscle [@bib19] ([Figure S1A](#s0125){ref-type="sec"}). The resulting muscle-specific knockout (hereafter referred to as mKO) mice showed a disrupted *Bmal1* gene in skeletal muscles but not in heart and liver ([Figure S1B](#s0125){ref-type="sec"}) and markedly decreased levels of BMAL1 protein in skeletal muscle ([Figure S1C](#s0125){ref-type="sec"}). *Bmal1* transcripts were reduced across the circadian cycle in both fast muscles (tibialis anterior, TA) and slow muscles (soleus, SOL) compared to control littermates (*Bmal1fl/fl; Cre−/−*), whereas *Bmal1* levels and rhythmic expression were unchanged in cardiac muscle ([Figure S1D](#s0125){ref-type="sec"}). We also generated an inducible muscle-specific *Bmal1* knockout line (hereafter referred to as imKO) by crossing floxed *Bmal1* mice with HSA-Cre-ER mice, in which the human skeletal actin promoter controls a chimeric Cre recombinase fused with a mutated estrogen receptor that can be activated by tamoxifen [@bib20] ([Figure S1E](#s0125){ref-type="sec"}). Two-month-old imKO mice and their control littermates were treated with tamoxifen daily for 5 days and examined at 1 or 5 months after tamoxifen treatment. Cre-mediated recombination of the *Bmal1* gene was seen in skeletal muscles but not in the heart ([Figure S1F](#s0125){ref-type="sec"}). Bmal1 transcripts were reduced across the circadian cycle in skeletal muscles from imKO mice after tamoxifen treatment ([Figure S1G](#s0125){ref-type="sec"}), and BMAL1 protein levels were likewise markedly reduced ([Figure S1H](#s0125){ref-type="sec"}).

The phenotype of mKO mice was strikingly different from that of whole body *Bmal1* knockout mice. Mice with whole body *Bmal1* knockout were reported to stop growing around 16 weeks of age, display progressive arthropathy, sarcopenia and loss of fat tissue, and die between 26 and 52 weeks of age [@bib39; @bib40]. In contrast, mKO mice had a normal life span ([Figure 1](#f0005){ref-type="fig"}A) and growth curve ([Figure 1](#f0005){ref-type="fig"}B), with body weight being slightly increased compared to controls at advanced age. The weight of both fast and slow hindlimb muscles was significantly increased compared to controls ([Figure 1](#f0005){ref-type="fig"}C). In contrast, no significant difference was seen in the weight of epididymal fat pads ([Figure 1](#f0005){ref-type="fig"}D). The fiber type profile of mKO mice was similar to controls, with the slow soleus predominantly composed of type 1 and 2A fibers, with few type 2X fibers, and the fast extensor digitorum longus (EDL) predominantly composed of type 2B and 2X fibers, with few type 2A fibers ([Figure 1](#f0005){ref-type="fig"}E). However, quantitative analysis revealed a slight decrease in type 1 and a corresponding increase in type 2A fibers in soleus, and a very slight decrease in the relative proportion of type 2X fibers in EDL ([Figure 1](#f0005){ref-type="fig"}F). Muscle histology was apparently normal in mKO muscles even at advanced age, with no sign of fiber degeneration or regeneration or fibrosis ([Figure 1](#f0005){ref-type="fig"}G). Muscle force, as determined *in vivo*, showed a significant decrease when normalized for muscle mass ([Figure 1](#f0005){ref-type="fig"}H). A similar decrease in muscle force was previously reported for whole body *Bmal1* knockout mice, which also show a disruption of sarcomere architecture, with loss of the regular disposition of thick and thin filaments [@bib41]. However, electron microscopy revealed no significant change in muscle ultrastructure of mKO muscles: in particular, sarcomeres showed regular banding pattern and the hexagonal disposition of thick and thin filaments in cross-section was normal ([Figure S2](#s0125){ref-type="sec"}).

The phenotype of imKO mice was similar to that of controls when examined at 1 or 5 months after tamoxifen treatment both with respect to body weight ([Figure 1](#f0005){ref-type="fig"}I) and muscle weight ([Figure 1](#f0005){ref-type="fig"}J). Muscle histology and fiber type profile were normal (not shown) and force production was not significantly different when compared to controls ([Figure 1](#f0005){ref-type="fig"}K). In contrast with global *Bmal1* knockout, which results in loss of circadian rhythm of locomotor activity and reduced total activity levels [@bib42], the circadian rhythm of locomotor activity was normal in muscle-specific *Bmal1* knockout and imKO mice, but surprisingly activity levels were increased during the dark phase in mKO mice ([Figure S3](#s0125){ref-type="sec"}).

3.2. Clock gene expression and circadian transcriptome changes in mKO muscles {#s0100}
-----------------------------------------------------------------------------

*Bmal1*-dependent genes, including *Rev-erbα*, *Rev-erbβ*, *Dbp*, *Tef*, *Hlf*, and *Cry2*, showed markedly reduced oscillation in TA muscles from mKO mice according to microarray analysis ([Figure 2](#f0010){ref-type="fig"}A) and qPCR of selected genes ([Figure S4](#s0125){ref-type="sec"}). Similar changes were detected in SOL muscles ([Figure S5](#s0125){ref-type="sec"}). *Per1* expression was also reduced, but *Per2* levels were only slightly affected. In contrast, *Clock, Npas2* and *E4bp4* (*Nfil3*) were all upregulated in mKO muscles. The *Bmal1* paralog, *Bmal2* (*Arntl2/Mop9*), which is downregulated in the liver of *Bmal1* null mice [@bib42] and can functionally replace *Bmal1* [@bib43], was found to be expressed at low levels without daily fluctuations in mouse skeletal muscle, and was unchanged in mKO muscles ([Figure S6](#s0125){ref-type="sec"}). The various responses of clock genes and clock-associated genes to *Bmal1* inactivation were in agreement with previous reports for global and tissue-specific *Bmal1* knockouts [@bib16]. For example, the fact that *Per2* oscillation was only mildly affected in mKO skeletal muscles likely reflects a role for oscillating systemic signals in the regulation of this gene, as was demonstrated in a liver-specific *Bmal1* knockout [@bib44; @bib45].

Global gene expression was markedly altered in skeletal muscles from mKO mice, with 931 genes in TA and 706 in SOL identified as differentially regulated according to maSigPro analysis ([Figure 2](#f0010){ref-type="fig"}B). Out of the 684 (Ctrl TA) and 1359 (Ctrl SOL) 24-h cycling genes identified by the JTK_CYCLE algorithm [@bib26], 487 genes in TA and 666 genes in SOL lost their 24-h oscillation in the absence of *Bmal1*, showing that a significant proportion of cycling genes in mouse skeletal muscles is controlled by the intrinsic muscle clock.

3.3. Impaired insulin-dependent glucose uptake in skeletal muscles from mKO and imKO mice {#s0105}
-----------------------------------------------------------------------------------------

Global changes in muscle gene expression were further examined by Gene Set Enrichment Analysis (GSEA) [@bib27] in order to identify significantly enriched signaling pathways altered by muscle-specific *Bmal1* knockout. The "KEGG insulin signaling pathway", comprising 132 genes coding for various components of the insulin-dependent signaling cascade, was among the top ranking gene sets altered in mKO muscles (*p*=0.024) in both TA ([Figure S7A](#s0125){ref-type="sec"}) and SOL muscles ([Figure S7B](#s0125){ref-type="sec"}). Transcriptome analysis indicated that the expression of a number of genes coding for major components of the insulin signaling pathway, including PI3K (p110), AKT1 and AKT2, were significantly up- or down-regulated in mKO muscles ([Figure S8](#s0125){ref-type="sec"}). Western blotting analyses showed that AKT2, the critical isoform in insulin-dependent glucose uptake, was also increased at the protein level in mKO muscles about 2-fold, whereas AKT1 was only slightly decreased ([Figure S9](#s0125){ref-type="sec"}).

To determine whether the gene expression changes shown by GSEA and Western blotting analysis lead to functional alterations in muscle insulin signaling, we measured rates of basal and insulin-stimulated glucose transport with \[^3^H\]-2-Deoxyglucose (2-DG) in isolated SOL muscles from mKO mice and their control littermates. Basal rates of 2-DG uptake were not different between control and mKO muscles, and the rate increased (+72%) in control muscle as expected in response to insulin. However, this increase was significantly reduced in mKO muscles (only +29%) ([Figure 3](#f0015){ref-type="fig"}A). Reduced sensitivity to insulin was even more striking in the inducible mKO model (imKO), in which no significant effect of insulin stimulation on glucose uptake was detected ([Figure 3](#f0015){ref-type="fig"}A). Next, we examined whether reduced muscle insulin sensitivity had consequences on global glucose homeostasis. Fasting blood glucose was unchanged in mKO mice both at ZT0 and ZT12 ([Figure 3](#f0015){ref-type="fig"}B). Glucose tolerance and insulin tolerance were likewise unchanged ([Figure 3](#f0015){ref-type="fig"}C and D), with similar results obtained in imKO mice ([Figure S10](#s0125){ref-type="sec"}).

Muscle insulin resistance induced by high-fat-diet or obesity is associated with dysregulation of the initial steps of insulin-signaling cascade leading to decreased AKT activation. We therefore examined the effect of insulin on AKT phosphorylation in the same muscles used for the glucose uptake assay. As shown in [Figure 3](#f0015){ref-type="fig"}E, a similar increase in insulin-stimulated AKT phosphorylation at Ser473 and Thr308 was detected in mKO and control muscles. Likewise, no significant difference in AKT phosphorylation was observed in muscles from mKO and control mice examined throughout the day/night cycle ([Figure 3](#f0015){ref-type="fig"}F). Interestingly, the diurnal cycle in phosphorylation state of AKT Ser473 in control muscle, peaking in the middle of the active/feeding phase, was unchanged in mKO muscle.

Next, we focused on the final steps of the insulin-signaling cascade directly involved in glucose uptake. The expression of GLUT4, the insulin-dependent glucose transporter, showed only modest, but significantly decreased expression at the transcript level (group effect *p*\<0.05, 2-way ANOVA; [Figure S8](#s0125){ref-type="sec"}). This change was even more evident at the protein level, with significant reductions particularly at ZT0, ZT12 and ZT16 ([Figure 3](#f0015){ref-type="fig"}G and H). Robust reductions in both transcript and protein levels were similarly observed for hexokinase 2 (HK2) ([Figures S8 and 3I, J](#s0125){ref-type="sec"}). AKT is known to control skeletal muscle glucose transport by phosphorylating the Rab-GTPase-activating proteins TBC1D4 (AS160) and TBC1D1, thus promoting the translocation of GLUT4 to the plasma membrane [@bib46; @bib47; @bib48]. As shown in [Figure 3](#f0015){ref-type="fig"}K and L, *Tbc1d4* transcript levels were essentially unchanged in mKO muscles, whereas *Tbc1d1* transcripts were markedly downregulated. Based on the JTK_CYCLE algorithm, and in agreement with circadian gene expression profiles obtained from high-resolution DNA microarray experiments (<http://bioinf.itmat.upenn.edu/circa/mouse>), *Tbc1d1* transcripts display a circadian rhythm in skeletal muscles with a peak during the active phase, and their oscillation is blunted in both slow and fast mKO muscles ([Figure 3](#f0015){ref-type="fig"}L). TBC1D1 protein levels were also markedly reduced across the day/night cycle in mKO muscles ([Figure 3](#f0015){ref-type="fig"}M and N). *Tbc1d1* was previously identified as a circadian gene also in bone and atrial myocardium [@bib49] and a comparative computational screen for conserved putative CLOCK:BMAL1-binding elements in the mouse and human genomes identified a potential *cis*-regulatory CLOCK:BMAL1 binding site within *Tbc1d1* [@bib50]. We observed that this 18 bp sequence is located in a non-coding region that is highly conserved among different mammalian species ([Figure S11](#s0125){ref-type="sec"}). Although a non-canonical E-Box, the core binding motif CACGGG was shown to efficiently bind the CLOCK:BMAL1 heterodimer in a screen for circadian transcription factor DNA binding activity [@bib51]. Interestingly, *Tbc1d1* knockout mice showed decreased insulin-dependent glucose uptake in isolated skeletal muscles, and GLUT4 protein abundance was similarly reduced by approximately 50% [@bib52].

3.4. Altered glucose metabolism in mKO muscles {#s0110}
----------------------------------------------

To gain further insight into the effect of muscle-specific *Bmal1* KO on glucose metabolism, we examined the circadian metabolome of control and mKO muscles. Diurnal steady state levels of glycolytic intermediates were similar in mKO and control muscles, with a tendency for the initial metabolites of the glycolytic pathway, such as glucose-6-phosphate and fructose-6-phosphate, to show distinct diurnal fluctuations, with peak levels during the active/feeding phase and reduced levels during the rest/fasting phase ([Figure 4](#f0020){ref-type="fig"}A). In contrast, mKO muscles showed significantly increased levels of a wide range of metabolites from pathways linked to glycolysis, including the pentose phosphate pathway (xylulose-5P, ribose, ribulose), the polyol pathway (sorbitol, galactitol, fructose) and the glucuronic acid pathway (xylitol, xylulose) ([Figure 4](#f0020){ref-type="fig"}B and [Table S1](#s0125){ref-type="sec"}). Interestingly, many of these sugar metabolites increased especially or exclusively during the active/feeding phase, i.e. the time when glycolytic intermediates were increased in both Ctrl and mKO muscles. To test whether muscle glucose oxidation was impaired in mKO muscles, we measured *in vitro* \[1-^14^C\]-glucose oxidation rates in control and mKO muscles around ZT12, at the start of the active/feeding phase. Glucose oxidation rate was significantly decreased by 37% in muscles from mKO mice compared to control, similar to the 51% reduction observed in control muscles after a 24-h fast ([Figure 5](#f0025){ref-type="fig"}A).

A crucial step in glucose oxidation is the irreversible oxidative decarboxylation of pyruvate to acetyl-CoA catalyzed by the pyruvate dehydrogenase (PDH) complex, a multisubunit mitochondrial complex. The PDH-E1α subunit catalyzes the rate-limiting step in the overall reaction, with the rate of conversion determined by the amount of PDH-E1α in the dephosphorylated active state (PDHa). We examined PDHa activity in muscles from control and mKO mice over 24 h and found that in control muscles, PDHa activity oscillated with a peak at ZT8-ZT12 ([Figure 5](#f0025){ref-type="fig"}B), immediately before and during the transition from the rest/fasting phase to the active/feeding phase. Similar diurnal fluctuations in PDHa activity were also reported in cardiac muscle [@bib53]. PDHa activity was significantly decreased in *Bmal*1 mKO skeletal muscles, and the normal peak during the light/dark transition was completely abrogated ([Figure 5](#f0025){ref-type="fig"}B). PDHa activity was similarly decreased in muscles from inducible knockout (imKO) mice ([Figure 5](#f0025){ref-type="fig"}C).

Reduced PDHa activity suggests increased phosphorylation of the E1α subunit of the PDH complex. Indeed, while protein levels of PDH-E1α were unchanged in mKO muscles ([Figure S12](#s0125){ref-type="sec"}), Ser300 phosphorylation, a site that increases in skeletal muscle after fasting [@bib54], was significantly increased in mKO muscles ([Figure 5](#f0025){ref-type="fig"}D). Reversible phosphorylation of PDH-E1α is controlled by PDH kinases (PDK) and PDH phosphatases (PDP). We therefore examined expression levels of *Pdk4* and *Pdp1*, the genes coding for the major PDK and PDP isoforms expressed in skeletal muscle. *Pdk4* was previously identified as a circadian gene in skeletal muscle [@bib55] and in many other tissues [@bib49]. As shown in [Figure 5](#f0025){ref-type="fig"}E, *Pdk4* displayed normal peak expression during the fasting phase in control muscles, but showed a marked shift in expression phase in mKO muscles, persisting at high levels well into the feeding phase. A similar shift in *Pdk4* expression was previously observed in muscles from a global *Clock* mutant [@bib55]. Consistent results were seen in imKO mice examined 5 months after tamoxifen treatment ([Figure S13](#s0125){ref-type="sec"}), again with *Pdk4* transcripts increased in imKO muscles at ZT12 compared to control littermates. PDK4 protein levels closely followed transcript levels, and were significantly increased in mKO muscles immediately before and during the active/feeding phase ([Figure 5](#f0025){ref-type="fig"}F). On the other hand, using JTK_CYCLE we identified *Pdp1* as a 24-h cycling gene in both TA and SOL muscles, with a peak between ZT8 and ZT12, i.e. in the hours preceding the active/feeding phase. *Pdp1* was also previously reported to be a circadian gene in the brain (listed as *Ppm2c*) [@bib49]. As shown in [Figure 5](#f0025){ref-type="fig"}G, *Pdp1* was markedly downregulated, and its oscillation completely abolished in muscles lacking *Bmal1*. Similar results were seen in muscles from the inducible knockout (imKO), with *Pdp1* transcripts clearly reduced at all timepoints 5 months after tamoxifen ([Figure S13](#s0125){ref-type="sec"}). PDP1 protein levels were similarly reduced across the day/night cycle in mKO muscles ([Figure 5](#f0025){ref-type="fig"}H and I). Potential CLOCK:BMAL1-dependent E-boxes have not been described for either *Pdk4* or *Pdp1*. However, *Pdp1* (listed as Gene ID 381511) was previously identified among the top 100 genes with conserved putative D-box *cis-*regulatory elements [@bib50]. The D-box transcriptional activators *Dbp*, *Hlf* and *Tef* are all direct targets of *Bmal1*, as is the D-Box transcriptional repressor *E4bp4* (*Nfil3*) [@bib8]. We found that this D-box sequence, located within the second intron of *Pdp1*, shows a high degree of conservation among many mammalian species in addition to human and mouse ([Figure S14](#s0125){ref-type="sec"}), suggesting *Pdp1* may be an indirect *Bmal1* target.

4. Discussion {#s0115}
=============

Skeletal muscle is a major site of insulin-stimulated glucose disposal [@bib56] and muscle insulin resistance has been considered to be one of the earliest factors in the pathogenesis of the metabolic syndrome [@bib57]. The dissection of the mechanisms controlling muscle insulin sensitivity may therefore have important implications for understanding the causes of metabolic diseases. Circadian rhythms control body metabolism and their disruption is known to increase the risk for metabolic syndrome; however the relative roles of central and peripheral clocks remain to be established. Changes in skeletal muscle structure and function were described in a global *Bmal1* knockout model [@bib41]; however it is unclear whether these are direct consequences of muscle *Bmal1* deficiency or secondary effects due to the disruption of the circadian pacemaker or other peripheral clocks. Global *Bmal1* knockout causes not only loss of circadian rhythm of locomotor activity but also reduced total activity levels [@bib42] and rescue experiments in which BMAL1 was constitutively expressed in skeletal muscle of *Bmal1* null mice showed that muscle-specific rescue restored activity levels, though not circadian rhythmicity of activity [@bib58]. This result was interpreted as indicating that BMAL1 function in muscle is important for activity. However, interpretation of this experiment is complicated by the fact that the *Bmal1* transgene used for the rescue was controlled by an α-actin promoter expressed at constitutively high levels in skeletal muscle, without any circadian oscillation.

We show here that muscle-specific *Bmal1* inactivation does not cause the dramatic changes seen in whole body *Bmal1* knockout, such as progressive sarcopenia and premature aging. The phenotype of both knockout models examined here was essentially normal, except for a slight change in fiber type composition and decrease in muscle force in the mKO but not in the imKO line. Locomotor activity showed a normal circadian rhythm in both lines; however the total activity levels during the dark phase were significantly increased compared to control in the mKO but not in imKO line. The cause of these differences remains to be established and probably reflects changes taking place during development in the mKO model. Importantly, in spite of these differences, the effect on glucose metabolism was essentially similar in the two muscle-specific *Bmal1* knockout lines.

The main result of this study is the finding that disruption of the intrinsic muscle clock causes muscle insulin resistance and altered muscle glucose metabolism. Insulin-dependent glucose uptake in isolated muscles was reduced by muscle-specific inactivation of *Bmal1*, induced either at early developmental stages (mKO) or in the adult (imKO). In contrast, no significant change in global glucose tolerance was observed in the absence of muscle *Bmal1*. Muscle insulin resistance without changes in global glucose tolerance was previously described in mice with muscle-specific knockout of the insulin receptor [@bib30]. It is likely that other insulin-sensitive tissues, such as adipose tissue, compensate for reduced muscle insulin sensitivity at the whole body level [@bib59].

What is the cause of the altered response to insulin in muscles from *Bmal1* mKO mice? The canonical insulin signaling pathway is apparently not responsible for this change, since AKT phosphorylation, which is reduced in obesity and diabetes [@bib60], was unchanged, and was similarly increased by insulin in muscles from control and *Bmal1* mKO mice ([Figure 3](#f0015){ref-type="fig"}E). Other experimental conditions, such as lipid infusion [@bib61; @bib62; @bib63], and skeletal muscle-specific genetic models, such as overexpression of PPARα [@bib64] or inactivation of carnitine acetyltransferase [@bib65], were also shown to cause muscle insulin resistance without affecting AKT phosphorylation. On the other hand, our results suggest that two major changes in muscle-specific *Bmal1* knockout muscles may be linked to muscle insulin resistance and altered glucose metabolism: (1) reduced GLUT4 protein levels, with reduced expression and altered circadian oscillation of TBC1D1; (2) reduced PDH activity due to altered expression of *Pdp1* and *Pdk4*, two circadian genes coding for the crucial PDH regulators ([Figure 6](#f0030){ref-type="fig"}).

In *Bmal1* mKO muscles, GLUT4 protein levels were significantly reduced by 45% across the diurnal cycle compared to control levels ([Figure 3](#f0015){ref-type="fig"}G and H). This change is likely relevant, because skeletal muscle-specific GLUT4^+/−^ mice, which have a 40--50% reduction in GLUT4 protein in skeletal muscles, also show a partial reduction in insulin-stimulated glucose uptake in skeletal muscles [@bib66]. GLUT4 traffic to the plasma membrane is controlled by two Rab-GTPase-activating proteins: TBC1D1 and its paralog TBC1D4 (AS160) [@bib67]. While *Tbc1d4* expression was essentially unaffected by *Bmal1* knockout, *Tbc1d1* was strongly downregulated in mKO skeletal muscle ([Figure 3](#f0015){ref-type="fig"}G and H) resulting in reduced circadian TBC1D1 protein levels ([Figure 3](#f0015){ref-type="fig"}M). Interestingly, *Tbc1d1* knockout mice were recently reported to show a 50% reduction in GLUT4 levels and impaired insulin-stimulated glucose uptake in skeletal muscle [@bib52]. A similar effect was previously described in a recombinant mouse strain carrying a mutation of *Tbc1d1* [@bib48; @bib68]. Our results therefore suggest that the loss of *Bmal1* in skeletal muscle leads to reduced *Tbc1d1* oscillation and expression levels, which in turn leads to reduced GLUT4 levels and insulin-stimulated glucose uptake, as previously suggested for the *Tbc1d1* knockout model [@bib52]. Interestingly, in both *Tbc1d1* null mice and mKO mice GLUT4 protein was markedly reduced, whereas *Glut4* mRNA levels were barely affected. In the case of *Tbc1d1* null mice, it was suggested that GLUT4 protein changes are not due to an alteration of transcriptional regulation of the gene, but reflect a post-translational event possibly controlled by TBC1D1 [@bib52]. One possibility is that TBC1D1 affects GLUT4 protein stability, but this remains to be established.

Glucose oxidation in *Bmal1* mKO muscles is impaired by reduced PDH activity due to altered expression of two circadian genes, *Pdp1* and *Pdk4*. During the rest/fasting phase, reduced insulin and contractile activity levels decrease glucose uptake and glycolytic flux in muscle cells, while promoting fatty acid β-oxidation, further inhibiting glucose oxidation by PDK4 activation and PDH inhibition [@bib69]. During the active/feeding phase, skeletal muscle glucose uptake and oxidation are both stimulated by a rise in blood glucose and insulin secretion, in conjunction with increased locomotor activity. At this stage, PDP1, which is stimulated by contractile activity-dependent increase in intracellular Ca^2+^, dephosphorylates PDH-E1α, thus activating the PDH complex. Our results suggest that circadian PDH activity is driven by the intrinsic muscle clock, with PDHa normally activated in anticipation of the active/feeding phase by increased expression of *Pdp1*. In the absence of *Bmal1*, *Pdp1* oscillation and expression is severely impaired, while *Pdk4* levels and PDH phosphorylation remain high also during the active/feeding phase. PDH thus remains partially "locked" in a fasting state during the light/dark transition when it is normally activated. We suggest that as a result of the PDH block, glycolysis is partially uncoupled from glucose oxidation in *Bmal1* KO muscles, and glycolytic flux in the context of PDH inhibition leads to the diversion of glycolytic intermediates to alternative metabolic fates, including the pentose phosphate and glucuronic acid pathways, with the shunting of glucose to the polyol pathway being favored by the concomitant decrease in HK2 levels ([Figure 6](#f0030){ref-type="fig"}).

In conclusion, we report here that a major physiological role of the muscle clock is to prepare muscle cells for the transition from the rest/fasting phase to the active/feeding phase, in anticipation of periodic fluctuations in fuel supply and demand. Reduced PDH activity and the concomitant block in insulin-stimulated glucose uptake are expected to impair the switch from lipid to glucose metabolism at the light/dark transition. Skeletal muscles with functional clocks are thus primed to choose "the right fuel at the right time" [@bib70], whereas muscle-specific *Bmal1* inactivation and the consequent disruption of the muscle clock would cause a state of reduced metabolic flexibility [@bib71], characterized by muscle insulin resistance and altered glucose metabolism.
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![Characterization of skeletal muscle-specific *Bmal1* knockout mice. (A) Survival curve of muscle-specific *Bmal1* knockout mice (mKO) and control littermates (Ctrl) (*n*=12/group). (B) Body weight of control and mKO mice (mean±SEM; *n*=7--10/group/age; \*\**p*\<0.01, 2-way ANOVA with the Bonferroni correction). (C) Weight of fast tibialis anterior (TA) and slow soleus (SOL) skeletal muscles from 5-month old mKO and control littermates (mean±SEM; *n*=36/group; \*\*\**p*\<0.001, Student\'s *t*-test). (D) Epididymal fat pad weight from 5-month old mKO and control littermates (mean±SEM; *n*=4/group). (E) Fiber type profile of slow soleus (SOL) and fast extensor digitorum longus (EDL) in transverse sections stained with anti-myosin antibodies specific for type-1/slow (blue), type-2A (green) and type 2B (red) myosin heavy chains. Type 2X fibers are unstained and appear black. Scale bar is 200 µμm. (F) Quantitation of the relative proportion of the different fiber types in SOL and EDL (mean±SEM, *n*=8 muscles per group with \>90% of fibers measured; see methods; \**p*\<0.05, Student\'s *t*-test). (G) Hematoxylin and eosin staining of transverse cryosections of SOL muscles from 26-month old mKO and control littermate. Scale bar is 50 µμm. (H) *In vivo* muscle force measurements performed on gastrocnemius muscles from 5-month old mKO and control littermates. Force normalized to muscle weight (mean±SEM, *n*=8--10 muscles per group; \*\**p*\<0.01, \*\*\**p*\<0.001, 2-way ANOVA with Bonferroni correction). (I) Body weight of 7-month old inducible muscle-specific *Bmal1* knockout mice (imKO, *n*=7) and control littermates (Ctrl, *n*=5) measured 5 months after tamoxifen injections (mean±SEM). (J) Weight of TA and SOL skeletal muscles from 7-month old imKO and control littermates measured 5 months after tamoxifen injections (mean±SEM; *n*=10--14/group). (K) *In vivo* muscle force measurements performed on gastrocnemius muscles from 7-month old imKO and control littermates 5 months after tamoxifen injection. Force normalized to muscle weight (mean±SEM, *n*=8--10 muscles per group).](gr1){#f0005}

![Altered gene expression caused by skeletal muscle-specific *Bmal1* knockout. (A) Circadian expression profiles of core clock and clock-associated genes in TA muscles from control and mKO mice. Transcript levels were determined by microarray analysis and plotted as mean absolute expression levels (mean±SEM; *n*=3/group/timepoint). (B) Phase map of differentially expressed genes in control and mKO skeletal muscles (TA and SOL) identified by maSigPro (see [Section 2](#s0010){ref-type="sec"}). Muscles were collected at 4-h intervals throughout the light (ZT0-ZT8, white box) and dark phase (ZT12--ZT20, black box) and hybridized to Affymetrix arrays as described in the methods (*n*=3/group/timepoint).](gr2){#f0010}

![Insulin-dependent glucose uptake is impaired by muscle-specific *Bmal1* deletion. (A) Insulin-stimulated \[^3^H\]-2-Deoxyglucose (2-DG) uptake by isolated SOL muscles from mKO (left panel) and imKO mice (right panel) versus respective controls (mean±SEM; *n*=15/group; \*\**p*\<0.01, \*\*\**p*\<0.001, Student\'s *t*-test). (B) Fasting blood glucose levels at ZT0 (*n*=6/group) and ZT12 (*n*=10/group) from Ctrl and mKO mice (mean±SEM). (C) Glucose tolerance test performed at ZT12 in mKO mice versus control (mean±SEM; *n*=10/group). (D) Insulin tolerance test performed at ZT12 in mKO mice versus control (mean±SEM; *n*=8/group). (E) Basal (−) and insulin-induced (+) AKT Ser473 and Thr308 phosphorylation determined in isolated SOL muscles from mKO and Ctrl mice. (F) *In situ* diurnal AKT Ser473 phosphorylation (*n*=5/group/timepoint) and Thr308 phosphorylation (*n*=3/group/timepoint) in mKO and Ctrl gastrocnemius muscle quantified by densitometry after western blotting analysis (mean±SEM; arbitrary units; AKT Ser473 time effect *F*=2.88, *p*=0.02, 2-way ANOVA). (G) Western blots showing protein levels of GLUT4 across the day/night cycle in mKO and Ctrl gastrocnemius muscles from 36 different mice (*n*=3/group/timepoint). (H) Diurnal protein levels of GLUT4 quantified by densitometry after western blot analysis (mean±SEM; arbitrary units; *n*=5/group/timepoint; \**p*\<0.05, \*\*\**p*\<0.001, 2-way ANOVA with Bonferroni correction, group effect *F*=32.2, *p*\<0.0001; time effect *F*=4.45, *p*=0.002; group×time interaction *F*=2.64, *p*=0.03). Right panel shows mean 24-h GLUT4 protein levels (mean±SEM; arbitrary units; *n*=30/group; \*\*\**p*\<0.0001, Student\'s *t*-test). (I) Western blots showing protein levels of HK2 across the day/night cycle in mKO and Ctrl gastrocnemius muscles from 36 different mice (*n*=3/group/timepoint). (J) Diurnal protein levels of HK2 quantified by densitometry after western blot analysis (mean±SEM; arbitrary units; *n*=3/group/timepoint; \**p*\<0.05, \*\**p*\<0.01, 2-way ANOVA with the Bonferroni correction, group effect *F*=57.8, *p*\<0.0001). Right panel shows mean 24-h HK2 protein levels (mean±SEM; arbitrary units; *n*=18/group; \*\*\**p*\<0.0001, Student\'s *t*-test). (K) and (L) Diurnal expression profiles of *Tbc1d4* (K) and *Tbc1d1* (L) transcripts in SOL and TA muscles from Ctrl and mKO mice detected by qPCR and plotted relative to *36B4* expression (mean±SEM; *n*=3/timepoint; \*\**p*\<0.01, \*\*\**p*\<0.001, 2-way ANOVA with the Bonferroni correction). (M) Western blots showing TBC1D1 protein levels at three time points in mKO and Ctrl TA muscles. (N) Mean 24-h TBC1D1 protein levels in mKO and Ctrl TA muscles (mean±SEM; arbitrary units; *n*=4/group; \*\**p*\<0.01, Student\'s *t*-test).](gr3){#f0015}

![Altered sugar metabolites in skeletal muscles from *Bmal1* mKO mice. (A) Diurnal variations of glycolytic metabolites in control (Ctrl) and mKO TA muscles (mean±SEM; *n*=5/group/timepoint; \**p*\<0.05, repeated measures ANOVA). (B) Diurnal changes of other sugar metabolites in Ctrl and mKO TA muscles (mean±SEM; *n*=5/group/timepoint; \**p*\<0.05, repeated measures ANOVA; see [Table S1](#s0125){ref-type="sec"}).](gr4){#f0020}

![Altered glucose metabolism in skeletal muscles from *Bmal1* mKO mice. (A) Glucose oxidation to CO~2~ measured in isolated diaphragms incubated with 5 mM \[1-^14^C\]-glucose at ZT12, at the light/dark transition (mean±SEM; *n*=5--10/group; \**p*\<0.05, \*\**p*\<0.01, Student\'s *t*-test). (B)--(D) Active pyruvate dehydrogenase (PDHa) activity and PDH phosphorylation in gastrocnemius muscles from Ctrl and mKO mice. (B) Diurnal pattern of PDHa activity. Data are expressed as mmoles/min/kg wet weight (mean±SEM; *n*=3/group/timepoint; 2-way ANOVA group effect *F*=6.66, *p*=0.016). Right panel shows mean 24-h PDHa activity in muscles from Ctrl and mKO mice (mean percent relative to control±SEM; *n*=18/group; \**p*\<0.05, Student\'s *t*-test). (C) Mean 24-h PDHa activity in muscles from Ctrl (*n*=13) and imKO mice (*n*=16) (mean percent relative to control±SEM; \**p*\<0.05, Student\'s *t*-test). (D) Diurnal PDH-E1α Ser300 phosphorylation quantified by densitometry after western blot analysis in muscles across the diurnal cycle (normalized to total PDH-E1α protein; mean±SEM; arbitrary units; *n*=3/group/timepoint; 2-way ANOVA group effect *F*=6.58, *p*=0.0173). Right panel shows mean 24-h PDH-E1α Ser300 phosphorylation in mKO and control muscles (mean±SEM; arbitrary units; *n*=18/group; \*\**p*\<0.01, Student\'s *t*-test). (E) Diurnal gene expression profiles of PDH kinase 4 (*Pdk4*) in Ctrl and mKO TA and SOL muscles detected by qPCR and plotted relative to *36B4* expression (mean±SEM; *n*=3/group/timepoint; \**p*\<0.05, 2-way ANOVA with the Bonferroni correction). (F) PDK4 protein levels in Ctrl and mKO muscles (gastrocnemius) immediately before and during the dark/active phase (average of values measured at ZT8, 12, 16 and 20) (mean±SEM; *n*=12; \**p*\<0.05, Student\'s *t*-test). (G) Diurnal gene expression profiles of PDH phosphatase 1 (*Pdp1*) in Ctrl and mKO TA and SOL muscles detected by qPCR and plotted relative to *36B4* expression (mean±SEM; *n*=3/group/timepoint; \**p*\<0.05, \*\**p*\<0.01, \*\*\**p*\<0.001, 2-way ANOVA with the Bonferroni correction). (H) Western blots showing PDP1 protein levels, as measured immediately before and during the dark/active phase, in mKO and Ctrl gastrocnemius muscles. (I) PDP1 protein levels in mKO and Ctrl muscles (gastrocnemius) immediately before and during the dark/active phase (ZT8-20; mean±SEM; arbitrary units; *n*=4/group; \*\**p*\<0.01, Student\'s *t*-test).](gr5){#f0025}

![Glucose metabolism in skeletal muscles of *Bmal1* mKO mice. In control mice glucose uptake is normally enhanced by insulin at the transition from the rest/fasting to the active/feeding phase, and PDH activity is increased by upregulation of PDP1 and downregulation of PDK4. In *Bmal1* mKO mice, insulin-dependent glucose uptake is impaired due to decreased GLUT4 and TBC1D1 protein levels. As a result of reduced HK2 and PDHa activity, glucose metabolism is channeled to alternative pathways, including the polyol, pentose phosphate and glucuronic acid pathways.](gr6){#f0030}
